Compare Stocks → New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:HOOKNASDAQ:JAGXNASDAQ:KMDANASDAQ:SEELNASDAQ:XERS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHOOKHookipa Pharma$0.76$0.73$0.41▼$2.05$75.45M1.02529,898 shs172,806 shsJAGXJaguar Health$0.18+6.0%$0.09$0.05▼$1.22$45.55M1.3584.79 million shs69.19 million shsKMDAKamada$5.10+0.4%$5.78$4.08▼$6.53$291.97M1.0421,148 shs6,510 shsSEELSeelos Therapeutics$0.34+3.0%$0.77$0.32▼$49.80$4.54M1.88414,729 shs272,346 shsXERSXeris Biopharma$1.76-1.1%$2.45$1.46▼$3.26$250.01M2.331.41 million shs1.09 million shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHOOKHookipa Pharma+0.31%-5.00%+4.03%+15.86%+4.00%JAGXJaguar Health+7.40%+64.74%+157.04%+74.83%-72.32%KMDAKamada+0.39%-1.92%-11.15%-13.12%+9.68%SEELSeelos Therapeutics+1.81%-28.07%-48.00%-73.39%-98.60%XERSXeris Biopharma-1.12%-13.30%-18.14%-26.97%-21.43%New crypto project uncovers 2,050% in 65 days (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHOOKHookipa Pharma3.6616 of 5 stars3.55.00.00.04.21.71.3JAGXJaguar HealthN/AN/AN/AN/AN/AN/AN/AN/AKMDAKamada4.128 of 5 stars3.55.00.00.02.61.73.1SEELSeelos Therapeutics1.5455 of 5 stars3.24.00.00.00.00.00.0XERSXeris Biopharma3.4963 of 5 stars3.52.00.04.20.02.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHOOKHookipa Pharma3.00Buy$5.17575.47% UpsideJAGXJaguar HealthN/AN/AN/AN/AKMDAKamada3.00Buy$11.00115.69% UpsideSEELSeelos Therapeutics2.33Hold$70.0020,610.06% UpsideXERSXeris Biopharma3.00Buy$4.88176.99% UpsideCurrent Analyst RatingsLatest SEEL, XERS, HOOK, KMDA, and JAGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024XERSXeris BiopharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.003/25/2024HOOKHookipa PharmaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$5.003/25/2024HOOKHookipa PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.503/7/2024KMDAKamadaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.003/7/2024XERSXeris BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.50 ➝ $6.001/30/2024HOOKHookipa PharmaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$6.00 ➝ $5.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHOOKHookipa Pharma$20.13M3.76N/AN/A$0.91 per share0.84JAGXJaguar Health$9.76M5.01N/AN/A$0.07 per share2.53KMDAKamada$142.52M2.06$0.43 per share11.91$4.25 per share1.20SEELSeelos Therapeutics$2.20M2.10N/AN/A($3.42) per share-0.10XERSXeris Biopharma$163.91M1.51N/AN/A($0.05) per share-35.20Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHOOKHookipa Pharma-$81.58M-$0.88N/AN/AN/A-405.28%-72.30%-40.51%5/9/2024 (Estimated)JAGXJaguar Health-$41.30MN/A0.00∞N/A-423.11%-837.11%-80.76%5/20/2024 (Estimated)KMDAKamada$8.28M$0.1534.0012.44N/A5.81%5.66%3.57%5/22/2024 (Estimated)SEELSeelos Therapeutics-$37.88MN/A0.00∞N/A-1,719.56%N/A-517.23%5/20/2024 (Estimated)XERSXeris Biopharma-$62.26M-$0.45N/AN/AN/A-37.98%-610.76%-19.15%5/14/2024 (Estimated)Latest SEEL, XERS, HOOK, KMDA, and JAGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/22/2024Q4 2023HOOKHookipa Pharma-$0.20-$0.11+$0.09N/A$3.60 million$7.41 million3/6/2024Q4 2023KMDAKamada$0.05$0.09+$0.04$0.09$37.71 million$36.43 million3/6/2024Q4 2023XERSXeris Biopharma-$0.09-$0.10-$0.01-$0.10$45.50 million$44.39 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHOOKHookipa PharmaN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/AKMDAKamadaN/AN/AN/AN/AN/ASEELSeelos TherapeuticsN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHOOKHookipa PharmaN/A3.503.50JAGXJaguar Health6.332.001.34KMDAKamadaN/A3.431.64SEELSeelos TherapeuticsN/A0.140.14XERSXeris Biopharma49.271.641.23OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHOOKHookipa Pharma63.88%JAGXJaguar Health12.04%KMDAKamada20.38%SEELSeelos Therapeutics23.37%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipHOOKHookipa Pharma5.82%JAGXJaguar Health0.16%KMDAKamada36.10%SEELSeelos Therapeutics5.40%XERSXeris Biopharma4.36%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableHOOKHookipa Pharma5698.95 million93.19 millionOptionableJAGXJaguar Health49276.22 million275.77 millionNo DataKMDAKamada37857.47 million36.73 millionOptionableSEELSeelos Therapeutics1513.68 million12.94 millionOptionableXERSXeris Biopharma377140.45 million134.33 millionOptionableSEEL, XERS, HOOK, KMDA, and JAGX HeadlinesSourceHeadlineXeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 51% stake, while 45% is held by institutionsfinance.yahoo.com - April 5 at 12:23 PMXeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)finance.yahoo.com - April 3 at 6:23 PMXeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conferencefinance.yahoo.com - April 2 at 8:50 AMXeris Biopharma (NASDAQ:XERS) Now Covered by Oppenheimermarketbeat.com - March 28 at 8:29 AMXeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for 2024 Growthproactiveinvestors.com - March 18 at 9:49 PMHere's What Analysts Are Forecasting For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) After Its Annual Resultsfinance.yahoo.com - March 9 at 1:59 PMXeris Biopharma (XERS) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 8 at 7:43 PMXeris Biopharma Holdings Inc (XERS) Reports Robust Revenue Growth in Q4 and Full Year 2023finance.yahoo.com - March 7 at 2:41 PMXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call Transcriptinsidermonkey.com - March 7 at 1:01 PMQ4 2023 Xeris Biopharma Holdings Inc Earnings Callfinance.yahoo.com - March 7 at 12:19 AMXeris Biopharma Shares Drop After Weak 4Q Resultsmarketwatch.com - March 6 at 7:18 PMXeris Pharmaceuticals GAAP EPS of -$0.10 in-line, revenue of $44.39M beats by $0.84Mmsn.com - March 6 at 7:18 PMXERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023investorplace.com - March 6 at 2:00 PMXeris Biopharma secures $200M in capital in debt refinancing deal; sees big 4Q revenue jumpproactiveinvestors.com - March 6 at 9:57 AMXeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimateszacks.com - March 6 at 9:16 AMXeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Eventsbusinesswire.com - March 6 at 7:02 AMXeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capitalbusinesswire.com - March 6 at 7:00 AMWhy Xeris (XERS) Might Surprise This Earnings Seasonzacks.com - March 5 at 10:46 AMXeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024businesswire.com - February 28 at 7:00 AM3 Breakout Stocks Under $5 to Buy for More Upsidetheglobeandmail.com - February 23 at 7:13 PMXeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conferencefinance.yahoo.com - February 5 at 9:27 AMBig Game or Small, Here's How to Go About Stalking a Traderealmoney.thestreet.com - February 3 at 6:45 PMXeris inks licensing deal with Amgen on former Horizon drugchicagobusiness.com - January 12 at 9:32 AMXeris Biopharma jumps on news of Amgen dealthepharmaletter.com - January 12 at 9:32 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsHookipa PharmaNASDAQ:HOOKHOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Jaguar HealthNASDAQ:JAGXJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.KamadaNASDAQ:KMDAKamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Seelos TherapeuticsNASDAQ:SEELSeelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.Xeris BiopharmaNASDAQ:XERSXeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.